You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 27, 2024

Claims for Patent: 8,198,235

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,198,235

Title:	Use of GILZ protein expressed in dendritic cells to modulate an antigen-specific immune response
Abstract:	The invention concerns the use of at least one: a) a GILZ protein, a functional fragment of at least 5 consecutive amino acids of said protein, a GILZ modulator, or a recombinant vector expressing same, isolated or expressed in modified dendritic cells, and b) an antigen of interest and/or a molecule allowing targeting and/or passage of the plasmic membrane of dendritic cells, to prepare a medicine for preventing and/or treating autoimmune, inflammatory diseases, allergies, graft rejection and graft-versus-host disease, cancers and pathogenic micro-organism infections.
Inventor(s):	Emilie; Dominique (Paris, FR), Cohen; Nicolas (Saint-Mande, FR), Lemoine; Francois (Montrouge, FR)
Assignee:	Assistance Publique-Hopitaux de Paris (Paris, FR)
Application Number:	11/575,073
Patent Claims:	1. A method for inducing antigen-specific suppressor/regulatory T lymphocytes in vitro, wherein said antigen is a Dermatophagoides pteronvssinus allergen, and wherein said method comprises: a1) preparing autologous dendritic cells expressing a GILZ protein; and b1) simultaneously or sequentially, incubating said autologous dendritic cells obtained in said preparing a1) with an antigen corresponding to the antigen of said antigen-specific suppressor/regulatory T lymphocytes, and a peripheral blood sample comprising CD4.sup.+ T cells. 2. The method according to claim 1, wherein in b1), said autologous dendritic cells are simultaneously incubated with said antigen and said peripheral blood sample. 3. The method according to claim 1, wherein in b1), said autologous dendritic cells are sequentially incubated with said antigen and said peripheral blood sample. 4. The method according to claim 1, wherein said antigen is a Dermatophagoides pteronyssinus (Der p 1, Der p 2) allergen. 5. The method according to claim 1, wherein said blood sample is a peripheral blood mononuclear cell (PBMC) sample. 6. The method according to claim 1, wherein said blood sample is an autologous peripheral blood mononuclear cell (PBMC) sample.

Details for Patent 8,198,235

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Greer Laboratories, Inc.	N/A	insects (whole body), mite dermatophagoides pteronyssinus	Injection	101835	09/15/1958	⤷ Try a Trial	2024-09-10
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.